CN101080221A - 抗药性细菌感染疾病的肠胃外综合治疗 - Google Patents

抗药性细菌感染疾病的肠胃外综合治疗 Download PDF

Info

Publication number
CN101080221A
CN101080221A CNA2006800013537A CN200680001353A CN101080221A CN 101080221 A CN101080221 A CN 101080221A CN A2006800013537 A CNA2006800013537 A CN A2006800013537A CN 200680001353 A CN200680001353 A CN 200680001353A CN 101080221 A CN101080221 A CN 101080221A
Authority
CN
China
Prior art keywords
drug
grow
compound
antibacterial agent
vancomycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800013537A
Other languages
English (en)
Chinese (zh)
Inventor
M·乔杜里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Venus Remedies Ltd
Original Assignee
Venus Remedies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Venus Remedies Ltd filed Critical Venus Remedies Ltd
Publication of CN101080221A publication Critical patent/CN101080221A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CNA2006800013537A 2005-02-14 2006-02-08 抗药性细菌感染疾病的肠胃外综合治疗 Pending CN101080221A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN308DE2005 2005-02-14
IN308/DEL/2005 2005-02-14

Publications (1)

Publication Number Publication Date
CN101080221A true CN101080221A (zh) 2007-11-28

Family

ID=36337659

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800013537A Pending CN101080221A (zh) 2005-02-14 2006-02-08 抗药性细菌感染疾病的肠胃外综合治疗

Country Status (15)

Country Link
US (2) US7960337B2 (enExample)
EP (1) EP1848413B1 (enExample)
JP (1) JP4918502B2 (enExample)
KR (2) KR20070085674A (enExample)
CN (1) CN101080221A (enExample)
AU (1) AU2006213441B2 (enExample)
BR (1) BRPI0607168A2 (enExample)
CA (1) CA2597812C (enExample)
ES (1) ES2482700T3 (enExample)
MX (1) MX2007009754A (enExample)
NZ (1) NZ555077A (enExample)
PT (1) PT1848413E (enExample)
UA (1) UA91208C2 (enExample)
WO (1) WO2006085337A1 (enExample)
ZA (1) ZA200704393B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104056250A (zh) * 2009-11-23 2014-09-24 丘比斯特药物股份有限公司 脂肽组合物和相关方法

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080227732A1 (en) * 2005-05-13 2008-09-18 Venus Remedies Limited Treatment and Control of Severe Infections Including Cystic Fibrosis
CN101129383B (zh) * 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方
CN101129382B (zh) * 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
CN101129381B (zh) * 2006-08-25 2012-02-01 天津和美生物技术有限公司 含β-内酰胺类抗生素和离子螯合剂的抗生素复方
GB2459126A (en) * 2008-04-10 2009-10-14 Peter Wilson Antimicrobial agent
CN102548552B (zh) * 2009-07-24 2016-06-01 田纳西大学研究基金会 作为抗结核剂的大观霉素酰胺
US8709310B2 (en) 2011-01-05 2014-04-29 Hospira, Inc. Spray drying vancomycin
ITLO20110001A1 (it) * 2011-05-03 2012-11-04 Fisiopharma Srl Flaconi di vancomicina cloroidrata con stabilità migliorata
RU2491921C1 (ru) * 2012-07-11 2013-09-10 Общество с ограниченной ответственностью "Опытно-технологическая фирма "Этрис" Способ лечения мастита у коров в сухостойный период
WO2014152996A1 (en) 2013-03-14 2014-09-25 Cubist Pharmaceuticals, Inc. Crystalline form of a beta-lactamase inhibitor
PE20160048A1 (es) * 2013-03-15 2016-02-12 Merck Sharp & Dohme Composiciones antibioticas de ceftolozano
US20140274996A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Tazobactam and ceftolozane antibiotic compositions
US9297295B2 (en) 2013-03-15 2016-03-29 Scuderi Group, Inc. Split-cycle engines with direct injection
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
WO2015035376A2 (en) 2013-09-09 2015-03-12 Calixa Therapeutics, Inc. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US8906898B1 (en) 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane
WO2015051101A1 (en) 2013-10-02 2015-04-09 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
BE1021242B1 (nl) * 2014-06-11 2015-09-08 Neogen N.V. Teicoplanine lyofilisaten
KR102603756B1 (ko) 2014-11-06 2023-11-16 셀리아 파마슈티칼즈 에이피에스 글리코펩티드 조성물
JP2019510076A (ja) * 2016-02-19 2019-04-11 フォルシュングスツェントルム ボルシュテル ライプニッツツェントルム フュール メディツィン ウント ビオヴィッセンシャフテン 細菌感染症を治療するための手段と方法
EP3454883A1 (en) 2016-05-09 2019-03-20 Xellia Pharmaceuticals ApS Stabilized glycopeptide antibiotic formulations
CN107661470A (zh) * 2016-08-29 2018-02-06 成都特兰辰亚生物科技有限公司 添加有萘夫西林钠治疗痢疾的组合物
EP4192247A4 (en) * 2020-08-04 2025-01-08 Harrow IP, LLC Antibacterial compositions and methods for fabricating thereof
US12343373B2 (en) 2020-10-30 2025-07-01 Somerset Therapeutics, Llc Glycopeptide antibiotics liquid formulations and methods and uses thereof
EP4014965A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
EP4014969A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
CN117899225A (zh) * 2024-01-19 2024-04-19 芮城绿曼生物药业有限公司 一种增强免疫力的兽用抗菌注射剂、制备方法及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775533A (en) * 1987-02-24 1988-10-04 Erbamont, Inc. Reconstitution of dry fill cyclophosphamide
US6660267B1 (en) * 1992-12-21 2003-12-09 Promega Corporation Prevention and treatment of sepsis
GB9500978D0 (en) * 1995-01-19 1995-03-08 Smithkline Beecham Plc Pharmaceutical formulations
CZ75597A3 (en) * 1995-07-17 1997-08-13 Fraunhofer Ges Forschung Biologically active, metal containing ribonucleotide polypeptide, process of its preparation and pharmaceutical composition containing thereof
JP4142149B2 (ja) * 1997-07-10 2008-08-27 明治製菓株式会社 バンコマイシンの凍結乾燥製剤
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
CA2413251C (en) * 2000-06-21 2012-06-12 Cubist Pharmaceuticals, Inc. Compositions and methods to improve the oral absorption of antimicrobial agents
US7378408B2 (en) * 2001-11-30 2008-05-27 Pfizer Inc. Methods of treatment and formulations of cephalosporin
US6900184B2 (en) 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104056250A (zh) * 2009-11-23 2014-09-24 丘比斯特药物股份有限公司 脂肽组合物和相关方法

Also Published As

Publication number Publication date
NZ555077A (en) 2010-03-26
ES2482700T3 (es) 2014-08-04
PT1848413E (pt) 2014-07-18
WO2006085337B1 (en) 2006-11-02
WO2006085337A1 (en) 2006-08-17
MX2007009754A (es) 2007-11-07
AU2006213441B2 (en) 2011-12-01
KR20090052893A (ko) 2009-05-26
JP2008530082A (ja) 2008-08-07
US20080188403A1 (en) 2008-08-07
JP4918502B2 (ja) 2012-04-18
US8778873B2 (en) 2014-07-15
AU2006213441A1 (en) 2006-08-17
EP1848413A1 (en) 2007-10-31
US7960337B2 (en) 2011-06-14
EP1848413B1 (en) 2014-04-09
CA2597812C (en) 2012-01-24
BRPI0607168A2 (pt) 2009-08-11
KR20070085674A (ko) 2007-08-27
ZA200704393B (en) 2008-09-25
CA2597812A1 (en) 2006-08-17
UA91208C2 (ru) 2010-07-12
US20110257079A1 (en) 2011-10-20

Similar Documents

Publication Publication Date Title
CA2597812C (en) Parenteral combination therapy for infective conditions with drug resistant bacterium
Prescott Beta‐lactam antibiotics: penam penicillins
JP6870029B2 (ja) セフトロザン抗生物質組成物
US20200093814A1 (en) Combination therapy with amidine substituted beta-lactam compounds and beta-lactamase inhibitors for infections with antibiotic resistant bacterial strains
WO2008025226A1 (en) The antibiotics composition comprising beta-lactam antibiotics and ionic chelating agents
CN101060846A (zh) 采用可用于注射的β－内酰胺酶抑制剂防止β－内酰胺酶介导抗生素抗性的成分
KR100900208B1 (ko) 감염의 치료에 대해 토탈 솔루션을 제공하는 항생제 배합물
AU2009285632A1 (en) Compositions and methods of treatment comprising ceftaroline
CN115581700A (zh) 质量稳定抑菌活性高的含头孢噻肟舒巴坦或头孢噻肟他唑巴坦的药物组合物
BRPI0612447A2 (pt) composição antibiótica de dose fixa, processo para a preparação de um produto de combinação antibiótica de dose fixa, processo para a preparação de uma injeção lìquida e usos de pó seco para injeção e injeção lìquida
WO2018025248A1 (en) Edta injection and process for making the same
WO2022028243A1 (zh) 复方氨基酸在制备提高细菌对抗生素敏感性药物中的应用
AU2010295269B2 (en) Compositions and methods for treating bacterial infections using ceftaroline
US20040176349A1 (en) Antibacterial composition
RU2641962C2 (ru) Инъецируемая ветеринарная композиция
EP2934524B1 (en) Penethamate veterinary injectable formulations
WO2020154498A1 (en) Combining metabolic stimulation and amino acids to sensitize tolerant bacteria to antibiotics

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20071128